206 related articles for article (PubMed ID: 37483605)
21. Identification of hepatitis B virus aetiologic antigens, HBx and Pre-S2, in diffuse large B-cell lymphoma.
Huang X; Young KH; Guo W; Wang Y; Wang X; Xi Y; Wang L; Bai O
J Viral Hepat; 2020 Sep; 27(9):948-950. PubMed ID: 32281709
[TBL] [Abstract][Full Text] [Related]
22. Hepatitis B virus-associated B-cell non-Hodgkin lymphoma in non-endemic areas in Western Europe: Clinical characteristics and prognosis.
Lemaitre M; Brice P; Frigeni M; Hermine O; Arcaini L; Thieblemont C; Besson C
J Infect; 2020 Feb; 80(2):219-224. PubMed ID: 31846632
[TBL] [Abstract][Full Text] [Related]
23. Clinicopathological and prognostic features of hepatitis B virus-associated diffuse large B-cell lymphoma: a single-center retrospective study in China.
Chen DG; Chen G; Wang C; Ke LF; Wu H; He HM; Yang Y; Chen YP
Infect Agent Cancer; 2021 Aug; 16(1):57. PubMed ID: 34404436
[TBL] [Abstract][Full Text] [Related]
24. Molecular heterogeneity of diffuse large B-cell lymphoma: implications for disease management and prognosis.
Rossi D; Gaidano G
Hematology; 2002 Aug; 7(4):239-52. PubMed ID: 14972786
[TBL] [Abstract][Full Text] [Related]
25. Chronic hepatitis B virus infection is associated with a poorer prognosis in diffuse large B-cell lymphoma: a meta-analysis and systemic review.
Rong X; Wang H; Ma J; Pan S; Wang H; Jing S; Su Y; Wang L; Zhao C
J Cancer; 2019; 10(15):3450-3458. PubMed ID: 31293649
[TBL] [Abstract][Full Text] [Related]
26. Clinicopathologic Features and Genomic Signature of De Novo CD5 + Diffuse Large B-Cell Lymphoma : A Multicenter Collaborative Study.
Sang W; Ma Y; Wang X; Ma Y; Shen Z; Gu W; Wang F; Ye J; Zhang C; Miao Y; Xu C; Liu Q; Li B; Tu J; Wang C; Shi Y; Sun S; Yan D; Song X; Sun C; Shao Y; Xu L; Li Z; Ma D; Xu K; Young KH; Liu H
Am J Surg Pathol; 2022 Nov; 46(11):1533-1544. PubMed ID: 36006771
[TBL] [Abstract][Full Text] [Related]
27. [Expression and Clinical Significance of EZH2 in Patients with Diffuse Large B Cell Lymphoma Accompanied by HBV Infection].
Zhang YT; Feng D; Wang Y; Li DP; Li ZY; Qiu TT; Xu KL
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Jun; 28(3):855-860. PubMed ID: 32552947
[TBL] [Abstract][Full Text] [Related]
28. Clinical Analysis and Prognostic Significance of Hepatitis B Virus Infections with Diffuse Large B-Cell Lymphoma.
Kang X; Bai L; Han C; Qi X
Cancer Manag Res; 2020; 12():2839-2851. PubMed ID: 32425598
[TBL] [Abstract][Full Text] [Related]
29. The impact of hepatitis B virus (HBV) infection on clinical outcomes of patients with diffuse large B-cell lymphoma.
Law MF; Lai HK; Chan HN; Ha CY; Ng C; Yeung YM; Yip SF
Eur J Cancer Care (Engl); 2015; 24(1):117-24. PubMed ID: 25848698
[TBL] [Abstract][Full Text] [Related]
30. Does the presence of hepatitis virus B and C influence the evolution of diffuse large B-cell lymphoma?
Rubio J; Franco F; Sánchez A; Cantos B; Méndez M; Calvo V; Maximiano C; Perez D; Millán I; Sánchez-Beato M; Provencio M
Leuk Lymphoma; 2015 Jun; 56(6):1686-90. PubMed ID: 25219591
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of hepatitis B virus, hepatitis C virus, and human immunodeficiency virus seroprevalence in patients with diffuse large B cell lymphoma and Hodgkin's lymphoma.
Mert D; Merdin A; Ceken S; Dal MS; Ertek M; Altuntas F
J Cancer Res Ther; 2021; 17(4):951-955. PubMed ID: 34528547
[TBL] [Abstract][Full Text] [Related]
32. The Spectrum of MYC Alterations in Diffuse Large B-Cell Lymphoma.
Xia Y; Zhang X
Acta Haematol; 2020; 143(6):520-528. PubMed ID: 32074595
[TBL] [Abstract][Full Text] [Related]
33. Clinical Significance of
Ting CY; Chang KM; Kuan JW; Sathar J; Chew LP; Wong OJ; Yusuf Y; Wong L; Samsudin AT; Pana MNBM; Lee SK; Gopal NSR; Puri R; Ong TC; Bahari SK; Goh AS; Teoh CS
Int J Med Sci; 2019; 16(4):556-566. PubMed ID: 31171907
[No Abstract] [Full Text] [Related]
34. Low incidence of hepatitis B virus reactivation during chemotherapy among diffuse large B-cell lymphoma patients who are HBsAg-negative/ HBcAb-positive: a multicenter retrospective study.
Ji D; Cao J; Hong X; Li J; Wang J; Chen F; Wang C; Zou S
Eur J Haematol; 2010 Sep; 85(3):243-50. PubMed ID: 20491883
[TBL] [Abstract][Full Text] [Related]
35. Prognostic impact of hepatitis C virus infection in patients with diffuse large B-cell lymphoma treated with immunochemotherapy in the context of a novel prognostic index.
Chen YY; Huang CE; Liang FW; Lu CH; Chen PT; Lee KD; Chen CC
Cancer Epidemiol; 2015 Jun; 39(3):382-7. PubMed ID: 25899771
[TBL] [Abstract][Full Text] [Related]
36. Concurrent and reactivation of hepatitis B virus infection in diffuse large B-cell lymphoma: risk factors and survival outcome.
Guo YF; Pan JX; Zhuang WH
Infect Agent Cancer; 2018; 13():40. PubMed ID: 30559832
[TBL] [Abstract][Full Text] [Related]
37. Prevalence and chemotherapy-induced reactivation of occult hepatitis B virus among hepatitis B surface antigen negative patients with diffuse large B-cell lymphoma: significance of hepatitis B core antibodies screening.
Elbedewy TA; Elashtokhy HE; Rabee ES; Kheder GE
J Egypt Natl Canc Inst; 2015 Mar; 27(1):11-8. PubMed ID: 25716703
[TBL] [Abstract][Full Text] [Related]
38. Genetics and diffuse large B-Cell lymphoma.
Niroula R; Butera J
R I Med J (2013); 2015 Nov; 98(11):23-6. PubMed ID: 26517251
[TBL] [Abstract][Full Text] [Related]
39. Distinct clinical and genetic features of hepatitis B virus-associated follicular lymphoma in Chinese patients.
Ren W; Wang X; Yang M; Wan H; Li X; Ye X; Meng B; Li W; Yu J; Lei M; Xie F; Jiang W; Kimby E; Huang H; Liu D; Li ZM; Wu K; Zhang H; Pan-Hammarström Q
Blood Adv; 2022 May; 6(9):2731-2744. PubMed ID: 35030632
[TBL] [Abstract][Full Text] [Related]
40. Lymphocyte/monocyte ratio and cycles of rituximab-containing therapy are risk factors for hepatitis B virus reactivation in patients with diffuse large B-cell lymphoma and resolved hepatitis B.
Wu CY; Hsiao LT; Chiou TJ; Gau JP; Liu JH; Yu YB; Wu YT; Liu CJ; Huang YC; Hung MH; Chen PM; Huang YH; Tzeng CH
Leuk Lymphoma; 2015; 56(8):2357-64. PubMed ID: 25459444
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
